Pyry Dillemuth, Tuomas Karskela, Abiodun Ayo, Jesse Ponkamo, Jonne Kunnas, Johan Rajander, Olli Tynninen, Anne Roivainen, Pirjo Laakkonen, Anu J. Airaksinen, Xiang-Guo Li
{"title":"用于脂肪酸结合蛋白 3 靶向 PET 成像的新型放射肽 [18F]FNA-S-ACooP 的放射合成、结构鉴定和体外组织结合研究。","authors":"Pyry Dillemuth, Tuomas Karskela, Abiodun Ayo, Jesse Ponkamo, Jonne Kunnas, Johan Rajander, Olli Tynninen, Anne Roivainen, Pirjo Laakkonen, Anu J. Airaksinen, Xiang-Guo Li","doi":"10.1186/s41181-024-00245-3","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Fatty acid binding protein 3 (FABP3) is a target with clinical relevance and the peptide ligand ACooP has been identified for FABP3 targeting. ACooP is a linear decapeptide containing a free amino and thiol group, which provides opportunities for conjugation. This work is to develop methods for radiolabeling of ACooP with fluorine-18 (<sup>18</sup>F) for positron emission tomography (PET) applications, and evaluate the binding of the radiolabeled ACooP in human tumor tissue sections with high FABP3 expression.</p><h3>Results</h3><p>The prosthetic compound 6-[<sup>18</sup>F]fluoronicotinic acid 4-nitrophenyl ester was conveniently prepared with an on-resin <sup>18</sup>F-fluorination in 29.9% radiochemical yield and 96.6% radiochemical purity. Interestingly, 6-[<sup>18</sup>F]fluoronicotinic acid 4-nitrophenyl ester conjugated to ACooP exclusively by <i>S</i>-acylation instead of the expected <i>N</i>-acylation, and the chemical identity of the product [<sup>18</sup>F]FNA-<i>S</i>-ACooP was confirmed. In the in vitro binding experiments, [<sup>18</sup>F]FNA-<i>S</i>-ACooP exhibited heterogeneous and high focal binding in malignant tissue sections, where we also observed abundant FABP3 positivity by immunofluorescence staining. Blocking study further confirmed the [<sup>18</sup>F]FNA-<i>S</i>-ACooP binding specificity.</p><h3>Conclusions</h3><p>FABP3 targeted ACooP peptide was successfully radiolabeled by <i>S</i>-acylation using 6-[<sup>18</sup>F]fluoronicotinic acid 4-nitrophenyl ester as the prosthetic compound. The tissue binding and blocking studies together with anti-FABP3 immunostaining confirmed [<sup>18</sup>F]FNA-<i>S</i>-ACooP binding specificity. Further preclinical studies of [<sup>18</sup>F]FNA-<i>S</i>-ACooP are warranted.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"9 1","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-024-00245-3","citationCount":"0","resultStr":"{\"title\":\"Radiosynthesis, structural identification and in vitro tissue binding study of [18F]FNA-S-ACooP, a novel radiopeptide for targeted PET imaging of fatty acid binding protein 3\",\"authors\":\"Pyry Dillemuth, Tuomas Karskela, Abiodun Ayo, Jesse Ponkamo, Jonne Kunnas, Johan Rajander, Olli Tynninen, Anne Roivainen, Pirjo Laakkonen, Anu J. Airaksinen, Xiang-Guo Li\",\"doi\":\"10.1186/s41181-024-00245-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Fatty acid binding protein 3 (FABP3) is a target with clinical relevance and the peptide ligand ACooP has been identified for FABP3 targeting. ACooP is a linear decapeptide containing a free amino and thiol group, which provides opportunities for conjugation. This work is to develop methods for radiolabeling of ACooP with fluorine-18 (<sup>18</sup>F) for positron emission tomography (PET) applications, and evaluate the binding of the radiolabeled ACooP in human tumor tissue sections with high FABP3 expression.</p><h3>Results</h3><p>The prosthetic compound 6-[<sup>18</sup>F]fluoronicotinic acid 4-nitrophenyl ester was conveniently prepared with an on-resin <sup>18</sup>F-fluorination in 29.9% radiochemical yield and 96.6% radiochemical purity. Interestingly, 6-[<sup>18</sup>F]fluoronicotinic acid 4-nitrophenyl ester conjugated to ACooP exclusively by <i>S</i>-acylation instead of the expected <i>N</i>-acylation, and the chemical identity of the product [<sup>18</sup>F]FNA-<i>S</i>-ACooP was confirmed. In the in vitro binding experiments, [<sup>18</sup>F]FNA-<i>S</i>-ACooP exhibited heterogeneous and high focal binding in malignant tissue sections, where we also observed abundant FABP3 positivity by immunofluorescence staining. Blocking study further confirmed the [<sup>18</sup>F]FNA-<i>S</i>-ACooP binding specificity.</p><h3>Conclusions</h3><p>FABP3 targeted ACooP peptide was successfully radiolabeled by <i>S</i>-acylation using 6-[<sup>18</sup>F]fluoronicotinic acid 4-nitrophenyl ester as the prosthetic compound. The tissue binding and blocking studies together with anti-FABP3 immunostaining confirmed [<sup>18</sup>F]FNA-<i>S</i>-ACooP binding specificity. Further preclinical studies of [<sup>18</sup>F]FNA-<i>S</i>-ACooP are warranted.</p></div>\",\"PeriodicalId\":534,\"journal\":{\"name\":\"EJNMMI Radiopharmacy and Chemistry\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-02-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-024-00245-3\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJNMMI Radiopharmacy and Chemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s41181-024-00245-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, INORGANIC & NUCLEAR\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Radiopharmacy and Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s41181-024-00245-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}
Radiosynthesis, structural identification and in vitro tissue binding study of [18F]FNA-S-ACooP, a novel radiopeptide for targeted PET imaging of fatty acid binding protein 3
Background
Fatty acid binding protein 3 (FABP3) is a target with clinical relevance and the peptide ligand ACooP has been identified for FABP3 targeting. ACooP is a linear decapeptide containing a free amino and thiol group, which provides opportunities for conjugation. This work is to develop methods for radiolabeling of ACooP with fluorine-18 (18F) for positron emission tomography (PET) applications, and evaluate the binding of the radiolabeled ACooP in human tumor tissue sections with high FABP3 expression.
Results
The prosthetic compound 6-[18F]fluoronicotinic acid 4-nitrophenyl ester was conveniently prepared with an on-resin 18F-fluorination in 29.9% radiochemical yield and 96.6% radiochemical purity. Interestingly, 6-[18F]fluoronicotinic acid 4-nitrophenyl ester conjugated to ACooP exclusively by S-acylation instead of the expected N-acylation, and the chemical identity of the product [18F]FNA-S-ACooP was confirmed. In the in vitro binding experiments, [18F]FNA-S-ACooP exhibited heterogeneous and high focal binding in malignant tissue sections, where we also observed abundant FABP3 positivity by immunofluorescence staining. Blocking study further confirmed the [18F]FNA-S-ACooP binding specificity.
Conclusions
FABP3 targeted ACooP peptide was successfully radiolabeled by S-acylation using 6-[18F]fluoronicotinic acid 4-nitrophenyl ester as the prosthetic compound. The tissue binding and blocking studies together with anti-FABP3 immunostaining confirmed [18F]FNA-S-ACooP binding specificity. Further preclinical studies of [18F]FNA-S-ACooP are warranted.